Cassava Sciences, Inc.

Cassava Sciences, Inc.

SAVA·NASDAQ

$1.96

-6.5%
HealthcareBiotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$94.44M
EPS-1.8800
P/E Ratio-1.04
Earnings Date03/16/2026

sava

Tax Payables

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Cassava Sciences, Inc.

Cassava Sciences, Inc. Competitors Analysis of Tax Payables

SAVA · NASDAQ
CompanyTax Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
PEPG logo
PepGen Inc.
NASDAQ:PEPG
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
0.00
N/AN/AN/A
OABI logo
OmniAb, Inc.
NASDAQ:OABI
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
Cassava Sciences, Inc.

Cassava Sciences, Inc. Fair Value Envelope

SAVA · NASDAQ

Our analysis suggests that SAVA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.955, this represents a potential HIDDEN relative to our calculated worth for Cassava Sciences, Inc..

Intrinsic Value
Current Price: $1.955